Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Imatinib in Hormone Refractory Prostate Cancer
NCT00861471Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- May 2005
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in prostate cancer (PCa), sponsored by NYU Langone Health. Started May 2005; status: terminated.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00861471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00861471.